Premium
Evaluation of Plasma Hormone Concentrations in Relation to Clinical Staging in Patients with Prostatic Cancer:BRITISH PROSTATE STUDY GROUP *
Publication year - 1979
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1979.tb02891.x
Subject(s) - testosterone (patch) , hormone , medicine , prostate cancer , cancer , gynecology , prostate , citation , prolactin , oncology , urology , endocrinology , library science , computer science
Summary— Plasma concentrations of testosterone, oestradiol‐1 7β, luteinising hormone (LH), follicle stimulating hormone (FSH), prolactin and growth hormone (GH) were measured in patients with histologically proven prostatic cancer, before any form of therapy was given for this disease. Patients were categorised according to UICC classification. No systematic change in the group means of any of these hormones was associated with the progression of the disease from the TO to the T4 stage. When multivariate analysis was applied to the combined intraprostatic (TO + T1 + T2) and extraprostatic (T3 + T4) tumour category in patients without clinically evident metastases (MO) a discrimination was observed, GH substantially contributing to the separation of the 2 groups. When plasma hormone data from patients classified as MO (without metastases) were compared with M1 patients (with metastases), mean GH values were significantly larger (P<0.02) in patients with metastases. GH was also a major contributory factor to the discrimination between the MO and M1 groups, using multivariate analysis. Testosterone group means for MO versus M1 were also significantly different (P<0.02).